InsidersTradesSigma
Follow the SCYNEXIS INC stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, SCYNEXIS INC has recorded 54 reports. Market capitalisation: €314.2m. The latest transaction was disclosed on 30 June 2026 (Attribution). Among the most active insiders: Angulo Gonzalez David. The full history is accessible without an account.
54
Insider Decl.
n/a
Thresholds
€245,993
4 ops.
Buy Volume
n/a
n/a
Sell Volume
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,951 of 29,063 companies
14.0
score / 100
Value14
Quality14
FCF yld-9.9%
Earn yld-16%
EV/EBITDA·
ROE-18%
Gross mgn18%
Net mgn-42%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 30 June 2026
Declarations54 total
2,875 sharesCommon StockSEC:0001296998-26-000002:0
2,875 sharesCommon StockSEC:0001219866-26-000002:0
2,875 sharesCommon StockSEC:0001286338-26-000002:0
2,875 sharesCommon StockSEC:0001237401-26-000002:0
108,695 sharesCommon StockSEC:0001644071-26-000002:0
Canonical exit: 30 Jun 2026 (T+90)
129,833 shares0Common StockSEC:0001193125-26-033583:0
129,833 shares0Common StockSEC:0001178253-26-000004:0
391,333 shares0Common StockSEC:0001178253-26-000003:0
32,500 shares@ US$0.7630.9% of flowCommon StockSEC:0001178253-25-000007:0
23,000 shares0Common StockSEC:0000950170-25-091602:0
23,000 shares0Common StockSEC:0000950170-25-091598:0
23,000 shares0Common StockSEC:0000950170-25-091589:0
23,000 shares0Common StockSEC:0000950170-25-091570:0
23,000 shares0Common stockSEC:0000950170-25-091562:0
23,000 shares0Common StockSEC:0000950170-25-091555:0
23,000 shares@ US$0.8425.8% of flowCommon StockSEC:0000950170-25-052675:0
5,000 shares@ US$1.077.2% of flowCommon StockSEC:0000950170-25-042838:0
92,511 shares0Common StockSEC:0000950170-25-009188:0
92,511 shares0Common StockSEC:0000950170-25-009173:0
262,927 shares0Common StockSEC:0000950170-25-009170:0
20,000 shares@ US$1.3736.2% of flowCommon StockSEC:0000950170-24-106610:0
Canonical exit: 11 Dec 2024 (T+90)
23,000 shares0Common StockSEC:0000950170-24-076239:0
23,000 shares0Common StockSEC:0000950170-24-076227:0
23,000 shares0Common StockSEC:0000950170-24-076203:0
23,000 shares0Common StockSEC:0000950170-24-076200:0
25 of 54 declarations
关于 SCYNEXIS INC
SCYNEXIS, Inc.（股票代码：SCYX）是一家在美国纳斯达克市场交易的美国上市生物技术公司。该公司定位为开发治疗难治性和耐药性感染的创新药物，历史重点是抗真菌疗法，最近战略性地转向严重罕见疾病。SCYNEXIS于1999年在特拉华州注册成立，总部位于新泽西州泽西城。在其最近的文件和公司通讯中，该公司将自己描述为一家临床阶段生物技术公司，专注于解决重大的未满足医疗需求。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001178253/000095017025038044/scyx-20241231.htm?utm_source=openai)） 在其大部分公司历史中，SCYNEXIS一直以ibrexafungerp为中心，该产品以BREXAFEMME®的名称销售，是一种口服非唑类抗真菌药物。该产品在治疗某些阴道酵母菌感染方面代表了重要的治疗进展，公司还探索了该分子更广泛的抗感染应用。最近，SCYNEXIS已表明其抗真菌基础之外的更广泛的管线战略，重点介绍了SCY-247和SCY-770等严重罕见疾病领域的项目。这种演变表明该公司正在努力围绕专有科学和利基临床需求构建更多样化的长期管线。（[nasdaq.com](https://www.nasdaq.com/press-release/scynexis-announces-u.s.-availability-of-brexafemmer-ibrexafungerp-tablets-the-first?utm_source=openai)） 从竞争角度来看，SCYNEXIS仍然是一家小型生物制药公司，因此具有该领域的典型特征：高科学风险、监管不确定性、对外部资本的依赖以及开发和商业化方面的重大执行风险。其差异化在于其抗真菌专业知识、在某些适应症中的首创或新型机制定位，以及通过合作释放价值的潜力。该公司相对较少的员工数量也凸显了精益的运营模式，这与处于开发阶段的生物技术公司而非完全规模化的商业制药公司相符。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001178253/000095017025038044/scyx-20241231.htm?utm_source=openai)） 近期发展对投资者尤其重要。在2025年和2026年，SCYNEXIS报告了将BREXAFEMME NDA转让给葛兰素史克（GSK）以进行潜在重新上市的进展，同时也在推进其内部控制项目。该公司在最近的更新中强调了SCY-770和SCY-247，表明管线正在重新定位以抓住罕见疾病机会。在资本市场方面，纳斯达克授予SCYNEXIS 180天的延期以重新符合最低股价要求，这表明股价持续面临压力。总而言之，这些发展使SCYNEXIS成为一个投机但可能有趣的生物技术故事，其上涨主要取决于临床执行、监管里程碑和战略合作。（[ir.scynexis.com](https://ir.scynexis.com/news-events/press-releases/detail/347/scynexis-reports-second-quarter-2025-financial-resultsand?utm_source=openai)）
